EMA/PE/0000233998
Submitted by Anonymous (not verified) on 14 July 2026 - 8:51
EMA/PE/0000233998
Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000241034
Submitted by Anonymous (not verified) on 14 July 2026 - 8:50
Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000241034
EMA/PE/0000240529
Submitted by Anonymous (not verified) on 14 July 2026 - 8:41
EMA/PE/0000240529
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths
Submitted by Anonymous (not verified) on 14 July 2026 - 8:00
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths
Submitted by Anonymous (not verified) on 14 July 2026 - 8:00
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalence guidance - various strengths
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalnce guidance - various strengths
Submitted by Anonymous (not verified) on 14 July 2026 - 8:00
Semaglutide and FlexTouch solution for injection in pre-filled pen product-specific bioequivalnce guidance - various strengths
Ixchiq
Submitted by Anonymous (not verified) on 14 July 2026 - 7:14
Ixchiq
Decision of the Executive Director on rules governing the traineeship programme at the EMA
Submitted by Anonymous (not verified) on 13 July 2026 - 16:58
Decision of the Executive Director on rules governing the traineeship programme at the EMA
SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 16:00 (CET)
Submitted by Anonymous (not verified) on 13 July 2026 - 16:33
SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 16:00 (CET)
Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 13 July 2026 - 16:25
Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 6, Status: Authorised